StemCell Therapy

DGAP-News: Evotec SE / Key word(s): Miscellaneous14.09.2020 / 07:30 The issuer is solely responsible for the content of this announcement.

Hamburg, Germany, 14 September, 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the French-based BIOASTER Technological Research Institute ("BIOASTER") today announced that they have entered into a partnership to advance research for infectious diseases. BIOASTER is a technology and innovation hub located in Lyon, France that has created a new model to address the latest challenges in the microbiology field, including antimicrobial resistance and vaccine safety and efficacy.

The organisations have been working together since the beginning of 2020 and Evotec represents the first global research and development company to locate staff in BIOASTER's premises in Lyon.

Under the terms of the collaboration agreement, the two organisations aim to put forward new research projects against infectious diseases and antimicrobial resistance, potentially creating new therapies and technologies. This collaboration had already started through the European research projects and development consortium ERA4TB (European Regimen Accelerator for Tuberculosis) and GNA NOW (Novel Gram-negative antibiotic now) within the AMR accelerator supported by the Innovative Medicines Initiative IMI2, aimed at reducing resistance to antibiotics and developing new therapeutic solutions.

"BIOASTER is proud to have support from the French and European leaders in diagnostics, vaccines, and animal health, and is pleased to formalise such a partnership with Evotec at the Lyon site. This allows BIOASTER to strengthen its agility and its capacity for technological innovation, in particular on antimicrobial resistance. BIOASTER now has a high-value network of close partners, which covers our four fields of application: antimicrobials, diagnostics, vaccines and microbiota understanding are key for manufacturers and patients alike," said Dr Philippe Archinard, President of IRT BIOASTER.

"The agreement will nurture the research ecosystem of Lyon Metropole and its Biodistrict, and impact on both national and European levels. The fact that Evotec, a company headquartered in Hamburg, Germany, chose to locate its unit dedicated to infectious diseases together with BIOASTER in the Biodistrict Lyon, reinforces the reputation of this French health ecosystem, while offering a more complete and more powerful technological toolbox to speed up industrialisation of innovations," said Emeline Baume, first vice president of Lyon Metropole.

"We are very glad to be partnering with BIOASTER, bringing Evotec's proven global resources for anti-infective research and drug development to Lyon," said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "Both Evotec and BIOASTER have made a long-term commitment to tackle the challenge of antimicrobial resistance and we are confident that together we will be able to efficiently drive forward the progress in this field with high and rising unmet medical need."

The two entities gather more than 120 researchers in total, share the same advanced infrastructures, including five BSL3 laboratories, with easy access to diverse equipments: this co-location creates a new pole of attraction, particularly suited to the expectations of industrials to accelerate and de-risk their product developments in infectious diseases.

ABOUT BIOASTER TECHNOLOGICAL RESEARCH INSTITUTECreated in 2012, following the French initiative of Technological Research Institutes, BIOASTER is a non-for-profit foundation developing a unique technological and innovative model to support the latest challenges in microbiology. In particular, BIOASTER uses and develops high value technological innovations that accelerate development of medical solutions for populations and personalized medicine.The aim of BIOASTER is to bring together academic, industry and its capacities and specific knowledge to develop and execute high impact collaborative projects requiring industry compatible innovative technologies.Key figures:* 4 fields of expertise: antimicrobials, diagnostics, microbiota, vaccines* BSL2 & BSL3 laboratories in Lyon and Paris* 100+ employees, including 80% of scientific experts, 17 nationalities* 66+ collaborative projects, involving 27 private partners, 29 public partners.www.bioaster.org

ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,300 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

14.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Read more here:
EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON - PharmiWeb.com

Debut Bio

SAN DIEGO (PRWEB) September 15, 2020

Debut Biotechnology, a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Labs Biotechnology Grand Challenge. Debut Bio is the inaugural recipient of the award, which honors the companys proposal on biosynthesis of monomers for aerospace applications.

In the proposal, Debut Bio details its ability to leverage the companys scalable biomanufacturing platform for bio- and metal-free synthesis of polymer precursors relevant for the aerospace industry. Debut Bios platform will provide AFRL with the ability to effectively and efficiently biomanufacture specialty ingredients needed for aerospace applications. In doing so, Debut Bio expects to reduce aerospace material costs and improve vehicle maintenance processes by extending service lifetimes.

The Air Force Research Lab has a well-documented history in discovering and leveraging breakthrough technologies. By offering a cell-free, continuous biomanufacturing process, we are excited to continue that legacy of innovation through our work with them, said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Cell-free biomanufacturing enables the quality manufacturing of high-value molecules at a price point that scales far beyond what is possible today. In bringing this approach to the AFRL, we hope to usher in a new era of biomanufacturing for high-value molecules that is scalable, economically viable, and results in solutions that are efficient and effective.

Debut Bio has applied its technology to the pharmaceutical and specialty ingredient industries, allowing customers to manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high-value specialty chemicals.

The Debut Biotechnology proposal provides a path to a scalable, bio- and metal free synthesis of key aerospace polymer precursors, explained Dr. Davide Simone, AFRLs technology advisor for biosynthesis of monomers for aerospace thermosets and senior research chemist. Expected benefits for the Air Force include a significant savings in composite aerospace structural material costs and the elimination of oxidation promoting metal catalysts from structural components, extending service lifetimes.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional materials manufacturing and avoids the use of environmentally harmful chemical synthesis. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing or extraction of ingredients from plants and other sources.

In Debut Bios system, materials are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based fermentation systems. The platform technology operates under a continuous manufacturing regime, allowing Debut Bio to scale beyond the capabilities of other manufacturing processes currently on the market, which are constrained by the precipitation of enzymes, the need for multiple large reactors, and the specific requirements of enzymes. By leveraging continuous manufacturing, Debut Bio is able to drive down the cost of cell-free manufacturing to provide scale, consistency, novelty, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio serves organizations across the defense and specialty ingredient industries, with commitments from several large scale manufacturers to integrate its platform into their existing pipelines.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Weiss, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Continued here:
Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications - PR Web

Nantkwest Inc (NK) is around the top of the Biotechnology industry according to InvestorsObserver. NK received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Nantkwest Inc also achieved a score of 79 in the Biotechnology industry, putting it above 79 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 62 means the stock is more attractive than 62 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Nantkwest Inc (NK) stock is trading at $7.94 as of 1:12 PM on Monday, Sep 14, a gain of $1.34, or 20.3% from the previous closing price of $6.60. The stock has traded between $6.84 and $7.97 so far today. Volume today is above average. So far 1,740,191 shares have traded compared to average volume of 1,370,495 shares.

Click Here to get the full Stock Score Report on Nantkwest Inc (NK) Stock.

Read the original post:
Where Does Nantkwest Inc (NK) Stock Fall in the Biotechnology Field? - InvestorsObserver

Evelo Biosciences Inc (EVLO) is around the middle of the Biotechnology industry according to InvestorsObserver. EVLO received an overall rating of 44, which means that it scores higher than 44 percent of all stocks. Evelo Biosciences Inc also achieved a score of 45 in the Biotechnology industry, putting it above 45 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Evelo Biosciences Inc (EVLO) stock is trading at $5.08 as of 2:35 PM on Monday, Sep 14, a rise of $0.39, or 8.32% from the previous closing price of $4.69. The stock has traded between $4.81 and $5.22 so far today. Volume today is less active than usual. So far 65,585 shares have traded compared to average volume of 145,817 shares.

Click Here to get the full Stock Score Report on Evelo Biosciences Inc (EVLO) Stock.

Originally posted here:
Is Evelo Biosciences Inc (EVLO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 70 rating InvestorsObserver gives to Avid Bioservices Inc (CDMO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 90 percent of stocks in the Biotechnology industry, CDMOs 70 overall rating means the stock scores better than 70 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Avid Bioservices Inc (CDMO) stock is trading at $7.69 as of 10:59 AM on Monday, Sep 14, a gain of $0.51, or 7.03% from the previous closing price of $7.18. The stock has traded between $7.27 and $7.78 so far today. Volume today is 347,046 compared to average volume of 413,400.

Click Here to get the full Stock Score Report on Avid Bioservices Inc (CDMO) Stock.

Here is the original post:
Where Does Avid Bioservices Inc (CDMO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Kolkata, Sep 14 (UNI) GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharmaceutical Ltd.) in collaboration with the Regional Centre for Biotechnology (RCB) has completed the first year of its Trust in Science Program and is marking it by hosting a six part Trust in Science webinar series. The first webinar was held today. Like the program, these webinars are also an academia-industry collaboration in which experts from the private sector and scientific community will provide insights on trends in bioinformatics and biostatistics and the future outlook of this valuable skill set. The Trust in Science program offers full PhD courses in Biostatistics and Bioinformatics to equip Indian students for a career in a data and AI-driven pharma research ecosystem.

Commenting on the progress of the program, Prof. Sudhanshu Vrati, Executive Director, Regional Centre for Biotechnology, said, Biostatistics and bioinformatics are rapidly emerging fields in biology and are set to change the way we approach scientific R&D. In the first year of this program, we got a good response from aspiring PhD candidates eager to explore scientific careers in these fields. Now, through our webinar series, we hope to reach out to even more Indian students and faculty to make them aware of the potential that lies in these fields and to realize the value of the Trust in Science PhD program.

In the keynote address, HE Jan Thompson, Acting British High Commissioner to India, said the Trust in Science initiative is a great example of public-private-partnership. She added, It is my hope that the Trust in Science initiative will give young researchers an opportunity to explore high-end expertise in drug discovery and the program becomes a spring-board for them to transition into a full-fledged pharma career in the future. The UK and Indian governments continue to work together in healthcare, exploring opportunities for some of the best UK companies to offer their products and services for improved healthcare delivery in India.

Dr. Renu Swarup, Secretary, Department of Biotechnology, Government of India, said, It is great to see that this RCB-GSK collaboration is more than a research budget collaboration between academia and industry, but one that looks to create a human resource foundation for new technology. I would like to see this partnership scaled up, with more partners included so that it becomes a national network for the country. I believe this webinar series can reach out to more people and draw in more institutes to see the value of this partnership..

Mr. Sridhar Venkatesh, Managing Director, GSK Pharmaceuticals Limited (India) said, The ongoing pandemic has highlighted the value of biostatistics and bioinformatics tools and methodologies to significantly reduce the time taken for a medicine to be brought from lab to market. This is the future of pharmaceuticals research and we believe that the Trust in Science programme is contributing to prepare a workforce that is future ready. We hope the webinar series will help aspiring PhD students to get a primer on the likely future of pharma research.

The launch webinar concluded with a learning session by Prof Partha Mazumdar, distinguished Professor, National Institute of Biomedical Genomics, who said, A confluence of statistical science and data science is the enabler of rapid and robust inferences in biology and medicine. He also spoke of the critical value of biostatistics and bioinformatics during the ongoing pandemic by referring to the study on the diversity and evolution of the coronavirus SARS-CoV-2 through the analysis of RNA sequences collected from 3636 infected patients across 55 countries. This is an exciting time in modern biology and medicine, he added, referring to the coming together of statics and big data analysis.

GSK Pharmaceutical Ltd.s Trust in Science initiative is a novel public-private partnership model to build R&D capacity for development and discovery in science. The pillars of this initiative are: scientific excellence, trust and talent development in line with GSKs Science, Technology and Culture values. The initiative was launched in 2011 initially to engage with leading researchers and institutions in Latin America, focused on Brazil and Argentina. GSK Pharmaceutical Ltd. is pleased to expand this initiative beyond Latin America to other emerging markets such as India.UNI SJC AND

Original post:
GSK Pharmaceuticals (India) in collaboration with Regional Centre for Biotechnology completes one year of 'Trust in Science' academia-industry...

A rating of 77 puts ChemoCentryx Inc (CCXI) near the top of the Biotechnology industry according to InvestorsObserver. ChemoCentryx Inc's score of 77 means it scores higher than 77% of stocks in the industry. ChemoCentryx Inc also received an overall rating of 60, putting it above 60% of all stocks. Biotechnology is ranked 31 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

ChemoCentryx Inc (CCXI) stock is trading at $53.41 as of 2:38 PM on Monday, Sep 14, an increase of $5.34, or 11.11% from the previous closing price of $48.07. The stock has traded between $48.54 and $53.69 so far today. Volume today is light. So far 346,181 shares have traded compared to average volume of 475,545 shares.

Click Here to get the full Stock Score Report on ChemoCentryx Inc (CCXI) Stock.

Read the original post:
Is ChemoCentryx Inc (CCXI) The Right Choice in Biotechnology? - InvestorsObserver

Denali Therapeutics Inc (DNLI) is near the top in its industry group according to InvestorsObserver. DNLI gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Denali Therapeutics Inc gets a 84 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Denali Therapeutics Inc (DNLI) stock is trading at $36.01 as of 3:36 PM on Monday, Sep 14, a rise of $4.02, or 12.57% from the previous closing price of $31.99. The stock has traded between $31.75 and $36.12 so far today. Volume today is high. So far 1,773,161 shares have traded compared to average volume of 842,601 shares.

Click Here to get the full Stock Score Report on Denali Therapeutics Inc (DNLI) Stock.

Link:
Is Denali Therapeutics Inc (DNLI) a Winner in the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Turning Point Therapeutics Inc (TPTX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, TPTXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Turning Point Therapeutics Inc (TPTX) stock is trading at $80.68 as of 2:39 PM on Monday, Sep 14, an increase of $9.58, or 13.47% from the previous closing price of $71.10. The stock has traded between $72.52 and $80.68 so far today. Volume today is 269,852 compared to average volume of 295,953.

Click Here to get the full Stock Score Report on Turning Point Therapeutics Inc (TPTX) Stock.

Read more from the original source:
Is Turning Point Therapeutics Inc (TPTX) a Winner in the Biotechnology Industry? - InvestorsObserver

The 47 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 50 percent of stocks in the Biotechnology industry, CARAs 47 overall rating means the stock scores better than 47 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cara Therapeutics Inc (CARA) stock is trading at $15.48 as of 1:09 PM on Monday, Sep 14, an increase of $0.57, or 3.82% from the previous closing price of $14.91. The stock has traded between $14.96 and $15.48 so far today. Volume today is 308,112 compared to average volume of 341,120.

Click Here to get the full Stock Score Report on Cara Therapeutics Inc (CARA) Stock.

View post:
Is Cara Therapeutics Inc (CARA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 51 rating InvestorsObserver gives to AIM ImmunoTech Inc (AIM) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 57 percent of stocks in the Biotechnology industry, AIMs 51 overall rating means the stock scores better than 51 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 51 would rank higher than 51 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

AIM ImmunoTech Inc (AIM) stock is trading at $1.80 as of 10:03 AM on Monday, Sep 14, a gain of $0.03, or 1.69% from the previous closing price of $1.77. The stock has traded between $1.78 and $1.84 so far today. Volume today is less active than usual. So far 108,630 shares have traded compared to average volume of 3,605,488 shares.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

See the article here:
Is AIM ImmunoTech Inc (AIM) The Right Choice in Biotechnology? - InvestorsObserver

A rating of 28 puts Clovis Oncology Inc (CLVS) near the bottom of the Biotechnology industry according to InvestorsObserver. Clovis Oncology Inc's score of 28 means it scores higher than 28% of stocks in the industry. Clovis Oncology Inc also received an overall rating of 36, putting it above 36% of all stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Clovis Oncology Inc (CLVS) stock is trading at $6.68 as of 10:47 AM on Monday, Sep 14, a rise of $0.64, or 10.52% from the previous closing price of $6.04. The stock has traded between $6.26 and $6.85 so far today. Volume today is below average. So far 3,761,442 shares have traded compared to average volume of 5,153,337 shares.

Click Here to get the full Stock Score Report on Clovis Oncology Inc (CLVS) Stock.

Read this article:
Should You Buy Clovis Oncology Inc (CLVS) in Biotechnology Industry? - InvestorsObserver

Axsome Therapeutics Inc (AXSM) is near the top in its industry group according to InvestorsObserver. AXSM gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Axsome Therapeutics Inc gets a 80 rank in the Biotechnology industry. Biotechnology is number 31 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Axsome Therapeutics Inc (AXSM) stock is trading at $82.28 as of 10:59 AM on Monday, Sep 14, an increase of $9.25, or 12.67% from the previous closing price of $73.03. The stock has traded between $74.40 and $82.40 so far today. Volume today is 290,235 compared to average volume of 369,883.

Click Here to get the full Stock Score Report on Axsome Therapeutics Inc (AXSM) Stock.

See the rest here:
Is Axsome Therapeutics Inc (AXSM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Global Blood Cell Analyzer Market to Reach $2. 1 Billion by 2027. Amid the COVID-19 crisis, the global market for Blood Cell Analyzer estimated at US$1. 5 Billion in the year 2020, is projected to reach a revised size of US$2.

New York, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Blood Cell Analyzer Industry" - https://www.reportlinker.com/p05960820/?utm_source=GNW 1 Billion by 2027, growing at aCAGR of 4.8% over the period 2020-2027. Semi-automated Biochemistry Analyzers, one of the segments analyzed in the report, is projected to record 4.5% CAGR and reach US$539.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fully Automated Biochemistry Analyzers segment is readjusted to a revised 4.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $439.7 Million, While China is Forecast to Grow at 4.5% CAGR

The Blood Cell Analyzer market in the U.S. is estimated at US$439.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$366.3 Million by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.We bring years of research experience to this 8th edition of our report. The 277-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05960820/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Global Competitor Market Shares Blood Cell Analyzer Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Blood Cell Analyzer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 2: World Historic Review for Blood Cell Analyzer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 3: World 15-Year Perspective for Blood Cell Analyzer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Semi-automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 5: World Historic Review for Semi-automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 6: World 15-Year Perspective for Semi-automated Biochemistry Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Fully Automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 8: World Historic Review for Fully Automated Biochemistry Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 9: World 15-Year Perspective for Fully Automated Biochemistry Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Bench-top by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 11: World Historic Review for Bench-top by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 12: World 15-Year Perspective for Bench-top by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Floor-standing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 14: World Historic Review for Floor-standing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 15: World 15-Year Perspective for Floor-standing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 17: World Historic Review for Clinical Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 18: World 15-Year Perspective for Clinical Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Drug development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 20: World Historic Review for Drug development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 21: World 15-Year Perspective for Drug development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 24: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 29: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 30: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 32: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 33: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 35: World Historic Review for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 36: World 15-Year Perspective for Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 38: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 39: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027

Table 41: World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 42: World 15-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Market Facts & Figures US Blood Cell Analyzer Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 43: USA Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 44: USA Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 45: USA 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 46: USA Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 47: USA Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 48: USA 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 49: USA Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 50: USA Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 51: USA 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 52: USA Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 53: USA Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 54: USA 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

CANADA Table 55: Canada Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 56: Canada Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 57: Canada 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 58: Canada Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 59: Canada Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 60: Canada 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 61: Canada Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 62: Canada Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 63: Canada 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 64: Canada Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 65: Canada Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 66: Canada 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

JAPAN Table 67: Japan Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 68: Japan Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 69: Japan 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 70: Japan Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 71: Japan Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 72: Japan 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 73: Japan Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 74: Japan Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 75: Japan 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

Table 76: Japan Current & Future Analysis for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 77: Japan Historic Review for Blood Cell Analyzer by End-Use - Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 78: Japan 15-Year Perspective for Blood Cell Analyzer by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2020 & 2027

CHINA Table 79: China Current & Future Analysis for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 80: China Historic Review for Blood Cell Analyzer by Product Type - Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 81: China 15-Year Perspective for Blood Cell Analyzer by Product Type - Percentage Breakdown of Value Sales for Semi-automated Biochemistry Analyzers and Fully Automated Biochemistry Analyzers for the Years 2012, 2020 & 2027

Table 82: China Current & Future Analysis for Blood Cell Analyzer by Modality - Bench-top and Floor-standing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 83: China Historic Review for Blood Cell Analyzer by Modality - Bench-top and Floor-standing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 84: China 15-Year Perspective for Blood Cell Analyzer by Modality - Percentage Breakdown of Value Sales for Bench-top and Floor-standing for the Years 2012, 2020 & 2027

Table 85: China Current & Future Analysis for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 86: China Historic Review for Blood Cell Analyzer by Application - Clinical Diagnostics, Drug development and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 87: China 15-Year Perspective for Blood Cell Analyzer by Application - Percentage Breakdown of Value Sales for Clinical Diagnostics, Drug development and Other Applications for the Years 2012, 2020 & 2027

See the original post here:
Global Blood Cell Analyzer Industry - Yahoo Finance

NEWARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, today announced the appointment of Rain co-founder Robert Doebele, MD, PhD, as chief scientific officer (CSO). Dr. Doebele has served as chair of the scientific advisory board and acting CSO since Rains founding. He will now transition to Rain full-time in the executive vice president (EVP) and CSO role, departing his position at the University of Colorado, Denver as associate professor of medicine. In his new role, Dr. Doebele will be responsible for leading Rains research and development efforts.

While at the University of Colorado, Dr. Doebele discovered NTRK1 fusions in lung cancer and pioneered the development of the pan-TRK inhibitor ARRY-470, subsequently renamed larotrectinib (VITRAKVI) from Loxo Oncology, and entrectinib (ROZLYTREK) from Ignyta Pharmaceuticals.

Working with Bob since the founding of Rain has been a great privilege, and we are thrilled to officially welcome him in a full-time capacity, said Avanish Vellanki, co-founder and chief executive officer of Rain. As a visionary leader in the precision oncology space with unparalleled experience in developing tumor-agnostic approaches to cancer treatment, we are in keen anticipation of Bobs impact on the corporate biotechnology industry post his departure from academia.

Dr. Doebele added, Rain is at a pivotal juncture in its evolution, and I am excited to transition full time to the company. Rains pipeline, which now includes RAIN-32, a potent MDM2 inhibitor, and a RAD52 inhibitor program in addition to our first clinical candidate, Tarlox, has the potential to make a transformative impact in the lives of patients with difficult-to-treat cancers. I look forward to leading the team as we develop tumor-agnostic, biomarker-driven trials to advance our targeted oncology candidates.

Dr. Doebele co-founded Rain Therapeutics in April 2017 and currently serves as chair of the scientific advisory board. Prior to joining Rain full time, Dr. Doebele served as associate professor of medicine in the division of medical oncology at the University of Colorado School of Medicine, director of the Thoracic Oncology Research Initiative at the University of Colorado Cancer Center and as principle investigator for the University of Colorado Lung Cancer Specialized Program of Research Excellence. In addition, he served as a senior editor of the AACR journal, Clinical Cancer Research and was elected to the American Society for Clinical Investigation in 2018. Dr. Doebele received his AB in molecular biology from Princeton University and received his MD and PhD in immunology from the University of Pennsylvania. He conducted his internal medicine residency and medical oncology fellowship at the University of Chicago.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rains lead program is RAIN-32, a small molecule MDM2 inhibitor for patients with well-differentiated and de-differentiated liposarcoma, and other indications exhibiting MDM2 gene amplification or overexpression. RAIN-32 has completed clinical trials in certain solid tumors and hematological malignancies and has received FDA Orphan Drug Designation for patients with liposarcoma. Tarloxotinib, a hypoxia-activated pan-HER inhibitor is in clinical trials for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations and HER2 activating mutations, as well as a tumor-agnostic cohort for patients with NRG1, EGFR, HER2, and HER4 fusions. Rain is also developing a potential first-in-class inhibitor of RAD52 in the DNA Damage Response (DDR) pathway as a synthetic lethal strategy for tumors with BRCA1/2 mutations. For more information, visit http://www.rainthera.com.

Media Contact for Rain

Cait Williamson, PhDLifeSci Communications+1.646.751.4366cait@lifescicomms.com

See the article here:
Rain Therapeutics Announces Appointment of Robert Doebele, MD, PhD as Executive Vice President and Chief Scientific Officer - GlobeNewswire

FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23rd.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference:Date: Wednesday, September 16th, 2020Location: https://wsw.com/webcast/hcw7/pdsb/1599649Time: 2:30 PM ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit:Date: Wednesday, September 23rd, 2020Location: https://wsw.com/webcast/oppenheimer5/pdsb/2703033Time: 4:10 PM ET

A replay of the Oppenheimer presentation will be available on the Companys website for 90 days following the event. Investors attending the conferences virtually who are interested in meeting with Company management should contact their H.C. Wainwright & Co. and Oppenheimer representatives.

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology platform. Versamune effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and include statements regarding the proposed public offering and anticipated closing. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including market conditions, whether the proposed offering is completed, the satisfaction of customary closing conditions related to the proposed offering and the other factors described in PDS Biotechs filings with the SEC. The information in this release is provided only as of the date of this release, and PDS Biotech undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media & Investor Relations Contact:

Deanne RandolphPDS BiotechnologyPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

James SaliernoThe Ruth GroupPhone: +1 (646) 536-7028 / +1 (973) 255-8361Email: jsalierno@theruthgroup.com

Link:
PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences - GlobeNewswire

Flow cytometry marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 7.51 billion by 2027 growing at a CAGR of 8.56% in the above-mentioned forecast period.

Flow Cytometry market analysis gives clear idea on various segments that are relied upon to observe the quickest business development amid the estimate forecast frame. This Flow Cytometry report indicates a professional and all-inclusive study of the market which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis. With the particular base year and the historic year, definite estimations and calculations are carried out in this report. The Flow Cytometry market research report displays a comprehensive study on production capacity, consumption, import and export for all the major regions across the globe.

Access Sample Copy of Research Report:https://databridgemarketresearch.com/request-a-sample/?dbmr=global-flow-cytometry-market

Some of the major players operating in this market are Bio-Rad Laboratories, Inc., Miltenyi Biotec Sysmex Partec GmbH, BIOMRIEUX, Mechatronics,, Apogee Flow Systems Ltd., Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher Scientific Inc., Merck KGaA, ACEA BIO, Agilent Technologies , Luminex Corporation. , Enzo Life Sciences, Inc., Beckman Coulter, Inc., Takara Bio Inc. among others.

North America dominates the flow cytometry market due to presence of supportive government reforms for the development of advanced technologies for molecular diagnostics, presence of a large number of clinical research labs and major pharmaceuticals in the U.S., while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to supportive government funding for the biotech industry development and presence of untapped opportunities, constantly improving healthcare infrastructure, rapid economic development, and rising patient awareness levels.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Flow cytometry market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for flow cytometry market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the flow cytometry market. The data is available for historic period 2010 to 2018.

Register Now @https://www.databridgemarketresearch.com/digital-conference/conference-on-rare-disease-and-orphan-drugs/group-delegate-registration

Global Flow Cytometry Market Drivers & Restraints:

The growing public-private initiatives in the field of immunology andimmuno-oncologyresearch will help in driving the growth of the flow cytometry market.

Increasing incidence and prevalence of HIV/AIDS and cancer, availability of application-specific products, growing adoption offlow cytometrytechniques in research and academia, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software along with technological advancement will likely to accelerate the growth of the flow cytometry market in the forecast period of 2020-2027.

On the other hand, evolving pipeline for stem cell research and adoption of recombinant DNA technology forantibodyproduction will further boost various opportunities that will lead to the growth of the flow cytometry market in the above mentioned forecast period.

Limited purchasing power of end users and significant product costs will likely to hamper the growth of the flow cytometry market in the above mentioned forecast period.

Segmentation:Global Flow Cytometry Market

By Technology

(cell-based flow cytometry, bead-based flow cytometry),

Products

(Reagents And Consumables, Flow Cytometry Instruments, Accessories, Services),

Application

(Research Applications, Clinical Application, Industrial Applications),

End User

(Academic & Research Institutes Pharmaceutical & Biotechnology Companies, Hospitals, Clinical Testing Laboratories, Blood Bank, Others),

Geography

(North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Any inquiry, Speak to Our Expert:https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-flow-cytometry-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:Sopan.gedam@databridgemarketresearch.com

Original post:
Global Flow Cytometry Market Current Trends And Efficient Techniques, Forecast 2027|Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher...

When close to half the companies in Taiwan have price-to-earnings ratios (or P/Es) below 18x, you may consider Universal Vision Biotechnology Co., Ltd. (GTSM:3218) as a stock to avoid entirely with its 65.8x P/E ratio. However, the P/E might be quite high for a reason and it requires further investigation to determine if its justified.

With earnings growth thats superior to most other companies of late, Universal Vision Biotechnology has been doing relatively well. The P/E is probably high because investors think this strong earnings performance will continue. If not, then existing shareholders might be a little nervous about the viability of the share price.

See our latest analysis for Universal Vision Biotechnology

Theres an inherent assumption that a company should far outperform the market for P/E ratios like Universal Vision Biotechnologys to be considered reasonable.

Retrospectively, the last year delivered an exceptional 51% gain to the companys bottom line. Pleasingly, EPS has also lifted 183% in aggregate from three years ago, thanks to the last 12 months of growth. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.

Shifting to the future, estimates from the two analysts covering the company suggest earnings should grow by 44% per annum over the next three years. With the market only predicted to deliver 8.8% per annum, the company is positioned for a stronger earnings result.

With this information, we can see why Universal Vision Biotechnology is trading at such a high P/E compared to the market. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

While the price-to-earnings ratio shouldnt be the defining factor in whether you buy a stock or not, its quite a capable barometer of earnings expectations.

As we suspected, our examination of Universal Vision Biotechnologys analyst forecasts revealed that its superior earnings outlook is contributing to its high P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings arent under threat. Unless these conditions change, they will continue to provide strong support to the share price.

You should always think about risks. Case in point, weve spotted 1 warning sign for Universal Vision Biotechnology you should be aware of.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a P/E below 20x.

PromotedIf youre looking to trade Universal Vision Biotechnology, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Go here to read the rest:
Market Participants Recognise Universal Vision Biotechnology Co., Ltd.s (GTSM:3218) Earnings - Simply Wall St

This report presents the worldwide Food Biotechnology market size (value, production and consumption), splits the breakdown (data status 2019 and forecast to 2025), by manufacturers, region, type and application.

This study also analyzes the Food Biotechnology market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the Food Biotechnology market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2759103&source=atm

The report provides a valuable source of insightful data for business strategists and competitive analysis of Food Biotechnology market. It provides the Food Biotechnology industry overview with growth analysis and futuristic cost, revenue and many other aspects. The research analysts provide an elaborate description of the value chain and its distributor analysis. This extensive Food Biotechnology study provides comprehensive data which enhances the understanding, scope and application of this report.

segment by Type, the product can be split intoTransgenic CropsSynthetic Biology Derived ProductsMarket segment by Application, split intoAnimalsPlantsOther

Market segment by Regions/Countries, this report coversNorthAmericaEuropeChinaJapanSoutheastAsiaIndiaCentral & South America

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2759103&source=atm

Regional Analysis for Food Biotechnology Market:

For comprehensive understanding of market dynamics, the global Food Biotechnology market is analyzed across key geographies namely: United States, China, Europe, Japan, and Rest of the World (South-east Asia, India, and others). Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding.

Influence of the Food Biotechnology market report:

-Comprehensive assessment of all opportunities and risk in the Food Biotechnology market.

Food Biotechnology market recent innovations and major events.

-Detailed study of business strategies for growth of the Food Biotechnology market-leading players.

-Conclusive study about the growth plot of Food Biotechnology market for forthcoming years.

-In-depth understanding of Food Biotechnology market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Food Biotechnology market.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2759103&licType=S&source=atm

The report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Food Biotechnology Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Food Biotechnology Market Size Growth Rate by Type

1.5 Market by Application

1.5.1 Global Food Biotechnology Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Food Biotechnology Market Size

2.1.1 Global Food Biotechnology Revenue 2014-2025

2.1.2 Global Food Biotechnology Production 2014-2025

2.2 Food Biotechnology Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio

2.3.2 Key Food Biotechnology Manufacturers

2.3.2.1 Food Biotechnology Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Food Biotechnology Product Offered

2.3.2.3 Date of Manufacturers in Food Biotechnology Market

2.4 Key Trends for Food Biotechnology Markets & Products

3 Market Size by Manufacturers

3.1 Food Biotechnology Production by Manufacturers

3.1.1 Food Biotechnology Production by Manufacturers

3.1.2 Food Biotechnology Production Market Share by Manufacturers

3.2 Food Biotechnology Revenue by Manufacturers

3.2.1 Food Biotechnology Revenue by Manufacturers (2019-2025)

3.2.2 Food Biotechnology Revenue Share by Manufacturers (2019-2025)

3.3 Food Biotechnology Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

View original post here:
Food Biotechnology Market : The report gives immense knowledge on the competitive nature of key players - Daily Research Chronicle

Report Highlights

Several significant developments have aided and accelerated the growth of markets in biotechnology, in the period of review. Notable recent advancements in biotechnology are CRISPR, Spheroids for drug development, Quantitative Cell Based Assay using high content analysis platform and Luciferase based high-throughput screening assay. Such technologies assure the wide adoption of cell line technologies for drug development, simplify the gene editing process making it cost-effective.

Companies operating in cell line market are investing huge amount in setting up manufacturing units with advanced state of art facility and expanded production facilities. At the same time, the genetic sequencing technology is advancing at a great pace especially in the healthcare sector in diagnosis of various cancers.

Gene therapy technology has opened new avenues which places emphasis on curing disease that do not have an effective therapeutic availability. Johnson & Johnson, together with the University of Pennsylvania, is developing a third-generation AAV-based gene therapy for Alzheimers disease. The goal is to use AAV viral delivery to initiate the expression of therapeutic anti-Alzheimers antibodies in the brain. Novartis launched Zolgensma for the treatment of spinal muscular atrophy. The research represents a novel way to get biologics into the brain to treat Alzheimers disease and other neurological diseases. This is expected to pave way for further innovations in AAV-based gene therapy.

The sector continuously faces some challenges related to marketing, paying for innovation, pricing pressures from the government organizations.

Paying for development costs is always most critical part for the manufacturers. In 2019, gene therapies and many cell biology technologies are developed to address the needs of some important diseases and proven to be effective. However, this comes for a high cost. For example, Zolgensma, a viral vector based gene therapy for the treatment of spinal muscular atrophy costs around $5 million. It is important to figure out how to pay for the innovation which is quite challenging.

The pricing and paying for getting the products to market are important challenges. The innovation may take several years from clinical trial phase to get launched in the market. The investors may be disappointed if the company doesnt show expected profits and loses the hope while stock prices fall. This means that companies must carefully manage expectations and maintain balance.

It includes highlights of reports published in 2019 on the following biotech markets:

Covid 19 Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/12599

Go here to see the original:
Biotechnology Research Market 2023: Potential growth, attractive valuation make it is a long-term investment - Scientect